Bacteriotherapy for inflammatory bowel disease

Yusuke Yoshimatsu, Yohei Mikami, Takanori Kanai

研究成果: Review article査読

抄録

The number of patients with inflammatory bowel disease is rapidly increasing in developed countries. The main cause of this increase is thought not to be genetic, but secondary to rapidly modernized environmental change. Changes in the environment have been detrimental to enteric probiotics useful for fermentation, inducing an increase in pathobionts that survive by means other than fermentation. This dysregulated microbiota composition, the so-called dysbiosis, is believed to have increased the incidence of inflammatory bowel disease. Bacteriotherapy, a treatment that prophylactically and therapeutically corrects the composition of disturbed intestinal microbiota, is a promising recent development. In fact, fecal microbiome transplantation for recurrent Clostridioides difficile infection in 2013 was a significant contribution for bacteriotherapy. In this paper, we comprehensively review bacteriotherapy in an easy-to-understand format.

本文言語English
論文番号3
ジャーナルInflammation and Regeneration
41
1
DOI
出版ステータスPublished - 2021 12

ASJC Scopus subject areas

  • 免疫アレルギー学
  • 免疫学
  • 細胞生物学

フィンガープリント

「Bacteriotherapy for inflammatory bowel disease」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル